Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
Clinical trial NCT05880927 · UNKNOWN
Trial details
- NCT number
- NCT05880927
- Sponsor
- Taizhou Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-01
- Primary completion
- 2024-12-31
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.